IMPORTANCE While the proportion of adults who smoke cigarettes has declined substantially in the past decade, socioeconomic disparities in cigarette smoking remain. Few interventions have targeted low socioeconomic status (SES) and minority smokers in primary care settings.
T obacco use is the leading cause of preventable morbidity and mortality in the United States. While the proportion of adults who smoke cigarettes has declined substantially in the past decade, socioeconomic disparities in cigarette smoking remain. In 2015, smoking prevalence among persons living below the poverty level (26.1%) was nearly double that of persons living at or above the poverty level (13.9%).
1 Smoking prevalence among persons of low socioeconomic status (SES) has remained high, despite populationbased interventions such as tobacco price increases and free access to tobacco cessation counseling and medications. Given that multicomponent interventions have shown the most promise in reducing health disparities, 2 we implemented a smoking cessation intervention among smokers at a safety-net hospital that included 2 approaches that have been used to address health disparities: (1) financial incentives; and (2) patient navigation, where a layperson from the community guides individuals through the health care system to receive appropriate services. Research has shown that financial incentives are effective for smoking cessation in an employed population, 3 among pregnant and newly postpartum women, 4 homeless smokers, 5 disadvantaged smokers who attended a tobacco cessation clinic, 6 as well as among lowincome smokers from the general population. 7 While 2 small randomized clinical trials (RCTs) 8, 9 have demonstrated feasibility and acceptability of patient navigation to promote smoking cessation among disadvantaged smokers, we are unaware of previous efficacy studies. We combined these 2 intervention components, anticipating that incentives would augment smokers' willingness to connect with a navigator and that the navigator would connect people with treatments through which incentives can work. In this RCT involving primary care patients at a large urban safety-net hospital, our objective was to evaluate the effect of a multicomponent financial incentives and patient navigation intervention in improving biochemically confirmed smoking cessation at 12 months. We hypothesized that the intervention would increase the likelihood of smoking cessation relative to an enhancement of usual care.
Methods

Design
The trial was a prospective, unblinded, RCT conducted from May 1, 2015, to September 4, 2017 (12-month follow-up data are presented) for low-SES and minority daily smokers receiving primary care at Boston Medical Center, a large urban safetynet hospital. The trial protocol is available in Supplement 1. 10 Through stratified randomization, participants were assigned to 1 of 2 groups. Enhanced traditional care control participants received a low literacy smoking cessation brochure 11 and a list of hospital and community resources for smoking cessation. Intervention participants received the same materials; in addition, they received up to 4 hours of patient navigation delivered over 6 months, and financial incentives for biochemically confirmed smoking cessation at 6 and 12 months following enrollment. We randomized participants using a random number generator with allocation concealment to a research assistant using sealed envelopes. Randomization was stratified by stage of change (contemplation vs preparation) with regard to smoking cessation. The primary outcome was biochemically confirmed smoking cessation at 12 months.
Ethics
The institutional review board (IRB) of the Boston University Medical Campus approved the trial, and written informed consent was obtained from all participants. The IRB advised that the exact dollar amount of the incentives not be noted in the informed consent owing to concerns about (1) retention in the control arm; (2) enrollment of "professional subjects"; and (3) potential coercion among low SES participants. Owing to concerns that the efficacy of the incentives was reduced by this approach, the study team obtained IRB approval to disclose the exact dollar amount of the incentives to intervention participants midway through the trial. Therefore, at the 6-month assessment, only some patients were aware of the exact dollar amount of the incentives. At the 12-month assessment, all intervention participants had been notified of the exact dollar amount of the incentives.
Participants
Recruitment took place May 2015 through March 2016 in Boston Medical Center's adult primary care waiting rooms. In addition, potentially eligible individuals identified in the primary care practice's patient registry received letters inviting them to participate in the study, with an opportunity to opt out of further study contact. Individuals who did not opt out received recruitment phone calls from a research assistant. Eligibility criteria included age of 18 years or older; smoking 10 or more cigarettes per day in the past week; contemplation or preparation stage of readiness to quit smoking; having a primary care clinician in the Section of General Internal Medicine or Department of Family Medicine; having telephone access; speaking English; and being able and willing to participate in the study protocol and provide informed consent. We excluded individuals who were actively using evidence-based smoking cessation treatment. In addition, we excluded Spanish-speaking patients as only 7% of adult primary care patients at Boston Medical Center speak Spanish.
Interventions
Conceptual Model
The Social Contextual Model 12 guided the interventions. The model presents aspects of the participants' social context, such as stress, financial problems, social networks, and multiple family roles that influence how population characteristics (race/ ethnicity and SES) might affect behavior patterns. Incorporating social contextual factors into intervention design has been shown to promote behavior change among racial/ethnic minority groups. 13 The theory of operant conditioning, 14 changing behavior by the use of reinforcement which is given after the desired response, guided the financial incentives intervention component.
Enhanced Traditional Care Control
In addition to traditional care, which consists of assessment of smoking status and brief cessation counseling, participants in this group received a low-literacy smoking cessation brochure 11 and a list of hospital and community resources for smoking cessation. Patient navigators did not interact with participants assigned to this group.
Patient Navigation and Financial Incentives
Participants in this group received the same materials as participants in the enhanced traditional care group. In addition, they were eligible to receive up to 4 hours of patient navigation delivered over 6 months. Two patient navigators received 10 hours of training in motivational interviewing techniques, 15 including use of a structured script (eAppendix in Supplement 2) and promotion of smoking cessation in underserved patient populations. One navigator had completed some college, had worked as a navigator in 3 previous trials of patient navigation, 8,16,17 and had served as a community health worker. The other navigator had a bachelor's degree in human services and had previously worked as a community health advocate and as an outreach coordinator for Boston's Mayor's Health Line. After enrollment, patient navigators contacted participants either to talk by phone or to arrange an inperson meeting. We did not designate a specific number of calls or meetings, but allotted a goal of 4 hours of patient navigation time per patient. The navigators identified and discussed salient social contextual factors using motivational interviewing techniques. 15 Among participants ready to quit smoking, the navigators directly connected patients to existing yet underused smoking cessation resources such as the Massachusetts quit line and the hospital-based smoking cessation group. The navigators also discussed medications; for participants interested in using bupropion or varenicline, the navigators helped to arrange follow-up with the participant's primary care clinician. For participants who desired nicotine replacement therapy (NRT), the navigator prompted the study physician (K.E.L.) to send prescriptions to the participants' pharmacies through the electronic health record (EHR). While not formally trained as tobacco treatment specialists, the navigators delivered some smoking cessation-related counseling. We defined the minimum navigation intervention dose as completion of the script incorporating motivational interviewing techniques, by telephone or in person.
A research assistant provided financial incentives following assessments and biochemically confirmed cessation. The distribution of incentives follows those in a previous study 3 : $250 for smoking cessation 6 months after study enrollment, as confirmed by a salivary cotinine, and an additional $500 for an additional 6 months after the initial cessation (12-month time point), confirmed by a salivary cotinine. Participants who did not quit smoking at 6 months and who had been unaware of the exact dollar amount of the incentive were given a "second chance" to quit smoking and earn $250 at 12 months, having been notified of the exact amount of the incentive. Study staff distributed incentives to patients who successfully quit smoking by providing a debit card loaded with the incentive amount.
Intervention Fidelity
During the intervention, 2 study investigators (K.E.L. and L.M.Q.) met weekly with the navigators to discuss their case load and to review their use of motivational interviewing techniques. We listened to audiotapes of navigation sessions and provided feedback on use of reflections and open-ended questions, and whether the navigators conveyed empathy and interacted with participants in a nonjudgmental manner.
Outcomes
The primary outcome was biochemically confirmed smoking cessation at 12 months. A research assistant, unblinded to study group assignment, attempted to contact all participants by telephone 6 and 12 months after enrollment, and asked whether they had stopped smoking. Participants who reported complete abstinence (not even a puff of a cigarette) for at least 7 days before being contacted during any follow-up interview were asked to come to the hospital to provide a saliva or urine sample for confirmation of smoking cessation with use of a cotinine (half-life, 17 hours) 18 or anabasine test (2 week detection window), 19 respectively. We considered a cotinine level of 10 ng/mL or less to indicate smoking cessation. 20 Among participants who were taking NRT, we considered an anabasine level of less than 3 ng/mL to indicate smoking cessation. 21 As smokers, we categorized all patients who self-reported abstinence, but were identified as smokers via biochemical validation; self-reported abstinence but refused biochemical verification; or could not be located. Participants in both study arms received $15 and $20, respectively, for completing each of the assessments. After each interview, participants in both study arms who reported that they had stopped smoking received an additional $15 for submitting a sample for biochemical verification. We obtained data on receipt of medications for smoking cessation (NRT, bupropion, and varenicline) and attendance at the hospital smoking cessation group via manual chart review. For all participants who were biochemically confirmed quit at 12 months, we reviewed all office visit notes to their primary care clinician for the 6 months following the date of their 12-month assessment, as well as the medical problem list, to ascertain documentation of current smoking. Finally, we obtained data from the Massachusetts Department of Public Health on participant use of the Massachusetts telephone quit line.
Covariates
We assessed the following sociodemographic variables at baseline: age, sex, marital status, insurance, income, education, employment, and racial/ethnic group. We measured levels of nicotine dependence with the Fagerström Test for Nicotine Dependence 22 and interest in quitting, as measured by stage of readiness to quit smoking. 23 We used validated measures of stress (the 4-item Perceived Stress Scale), 24 chaos (a 6-item Chaos Scale), 25 and hassles (the 9-item Abbreviated Hassles Index) 26 to assess life circumstances that may be barriers to cessation.
Statistical Methods
We estimated that at 12 months, 5% of participants in the enhanced traditional care study arm would quit smoking, relative to 20% of participants in the navigation and incentives study arm. We based these estimates on data from prior smoking cessation studies that included low SES adult smokers.
9,27
We recruited 175 smokers in the enhanced traditional care control arm and 177 smokers in the navigation and incentives arm, with 88% power to detect a 5% vs 20% difference in cessation rates between the 2 groups, with a 2-sided α of 0.05.
Analyses
The primary analysis was an intention-to-treat analysis of the difference in the likelihood of biochemically confirmed cessation between the enhanced traditional care control and navigation and incentives groups at 12 months. The similarity of the study groups with respect to covariates at baseline was analyzed by the χ 2 test for categorical variables and the Student t test for continuous variables. We used multivariable logistic regression to control for potential confounders identified in bivariable analyses as well as variables of a priori clinical significance 28,29 (sex, age, race/ethnicity, income, education, and receipt of an NRT prescription). Because few patients quit smoking in either study arm, we evaluated the adjusted models by including only 2 parameters in addition to the intervention group variable. We examined the effect of the intervention variable, and controlling for age, then each of the additional variables as a third variable. We expected the majority of missing data to be due to moving or failure to remain in the study. We investigated whether missing data was associated with patient characteristics. We analyzed Pearson correlation coefficients to identify collinearity among variables in the model; the correlation between variables ranged from −0.16 to 0.17 suggesting the absence of collinearity. Variance inflation factors for the predictors were all below 1.5, also suggesting no evidence of collinearity in the regression model. All analyses were conducted using SAS version 9.1 (SAS Institute Inc).
Results
This study assessed 892 patients for eligibility and randomized 352. The Figure shows reasons for exclusion, randomization, and follow-up, and Table 1 shows descriptive characteristics for the enhanced traditional care control and navigation and financial incentives groups. The 2 groups were not different in demographic and smoking characteristics. The majority reported belonging to a racial/ethnic minority group, having low income (≤$20 000/y), and low educational attainment (high school graduate or less). Participants smoked a mean of 15 cigarettes per day. Fifty-two participants in the navigation and incentives group (29.4%) were lost to follow-up or withdrew in the first 6 months, relative to 32 participants in the control group (18.3%) (P = .01). Participants lost to follow-up at 6 months were more likely to be male or white. At 12 months, 48 participants (27.1%) and 53 participants (30.3%) were lost to follow-up in the navigation and incentives group and the enhanced traditional care control group, respectively (P = .51). Participants who were lost to follow-up at 12 months were younger and more likely to be male than patients who were retained. Few participants in either study arm used the hospital smoking cessation group or the telephone quit line. Participants in the intervention group were more likely to receive prescriptions for NRT. The 6-month cessation rate, as confirmed by cotinine testing, was 9.6% in the navigation and incentives group compared with 0.6% in the control group (P < .001) ( Table 2) . Participants who were and were not aware of the exact dollar amount of the incentives had similar rates of biochemically verified cessation (10.4% and 8.6%, respectively; P = .69).
Within the intervention group, navigators were unable to contact 25 participants (14%); the navigators contacted an additional 25 participants (14%) but were unable to engage the participant in a discussion about smoking. For an additional 35 participants (20%), the navigators met the participant in person or provided navigation by phone but were not able to complete the motivational interviewing script. Thus, 93 participants (52%) received the minimum navigation intervention dose. Members of the navigation and incentives group who received the minimum navigation intervention dose had significantly higher rates of cessation at 6 months (n = 15 [16.1%]) than those who did not receive the minimum dose (n = 2 [2.4%]) (P ≤ .001). The navigators prompted the study physician to send a prescription for nicotine replacement therapy to the participants' pharmacy for 60 participants (34%). Five percent of intervention participants attended a hospital-based smoking cessation group or had a visit with a smoking cessation counselor.
At the 12-month assessment, 21 participants (11.9%) of participants in the navigation and incentives group compared with 4 participants (2.3%) in the control group, had quit smoking based on biochemical verification (P ≤ .001). Members of the navigation and incentives group who received the minimum navigation intervention dose had significantly higher rates of cessation at 12 months (n = 17 [18.3%]) than participants who did not receive the minimum dose (n = 4 [4.8%] (P ≤ .001). Eighty-one percent of participants in the intervention arm who quit smoking at 12 months received the minimum navigation intervention dose. Seven of 25 participants (28%) who had biochemically validated abstinence at 12 months had a note regarding current smoking on medical record review. By study arm, 5 of 21 intervention participants (23.8%) had documentation of current smoking relative to 2 of 4 (50%) of control participants (P = .29). Twelve participants (7%) in the navigation and incentives group were abstinent at both the 6-month and 12-month assessments, relative to 0% of the control participants (P ≤ .001).
Stratified analyses demonstrated that the navigation and incentives intervention was particularly beneficial for older participants, women, nonwhite participants, those with the lowest incomes, non-heavy smokers, and those in the contemplation stage with respect to smoking cessation ( Table 3) .
The odds ratio (OR) for quitting at 12 months was significantly higher in the navigation and incentives group than in the control group in the unadjusted model (OR, 5.76; 95% CI, ). In the adjusted models, older participants, women, and those who had NRT prescribed had an increased odds of quitting at 12 months ( Table 4 ). The average dollar amount per participant that was paid out for smoking cessation was $480.77. 34 Given that our navigators were most easily able to access nicotine replacement therapy for study participants, white smokers, who may have benefited from varenicline, were at a disadvantage. It is remarkable that so many participants in the intervention arm quit smoking, given that so few used medications to quit. By using a medication to quit smoking, individuals are 2 to 3 times more likely to quit smoking. [35] [36] [37] Multiple studies have demonstrated underutilization of pharmacotherapy and enduring misconceptions about pharmacotherapy, particularly among black smokers. 8, 38 We had anticipated that a patient navigator, as a layperson from the participants' community, might be able to address these misconceptions.
The fact that 1 of 3 of intervention participants had a prescription for NRT sent to their pharmacy suggests that the navigators were successful with regard to NRT. At the time of the intervention, the EAGLES trial, 39 which showed no significant increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo,
had not yet been published. Future patient navigation interventions could focus on linking more patients to varenicline therapy, particularly white smokers. Similarly, very few participants referred to smoking cessation counseling resources actually used those services. In future iterations, patient navigators should be trained as bona fide smoking cessation counselors so that they may provide cessation counseling to patients during their contacts.
Limitations
This study had several limitations. It is unclear whether abstinence at either of the 2 assessment points was transient or long lasting. Our findings may not be generalizable to safetynet settings with large numbers of uninsured smokers. In our study, the majority of participants had Medicaid, which covers nicotine replacement therapy. Our study is also limited by the fact that we cannot discern the relative contribution of the intervention components. Given that 81% of participants in the intervention arm who quit smoking at 12 months received the minimum navigation intervention dose, we believe that the navigation component was necessary. At the same time, we suspect that navigation alone would have been insufficient to achieve the smoking cessation rates we observed. Patient navigation has been shown to help patients achieve discrete, short-term behavior change (eg, completing a colonoscopy) 16 yet may be less effective in promoting complex behavior change as is required to quit smoking. This study also had a number of strengths. These included use of biochemical verification of self-reported abstinence and targeting a population of primary care smokers who were not already in treatment, hence testing the intervention on a broader, non-treatment-seeking population of smokers. 
Conclusions
This study shows that smoking cessation rates among adult daily smokers at a safety-net hospital who received patient navigation and financial incentives to quit smoking were significantly higher than the rates among smokers who were given program information but no navigation and financial incentives. Future research should assess how the effectiveness of this intervention can be maximized and how health care systems can implement patient navigation and incentives into primary care. Role of the Funder/Sponsor: The funder/sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. If you answered Yes above, indicate in the text box below; the names of the non-BUMC investigators, all study activities they will be performing, the names of their institutions, and why they are determined to be NOT-Engaged in the research (based on the OHRP engagement guidance).
Scott Halpern, MD from the University of Pennsylvania is a consultant who will provide expertise on financial incentives. He will have no contact with study subjects, and will only review analyses of deindetified data in aggregate.
Lori Pbert, PhD from the University of Massachusetts is a consultant who will provide expertise on smoking cessation. Similarly, she will have no contact with study subjects, and will only review analyses of deindetified data in aggregate.
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Cigarette smoking is a significant health threat. To eliminate disparities in cancer burden, smoking rates must be reduced among populations where smoking is disproportionately concentrated: those with low socioeconomic status (SES). We will apply two methods that are being used in the field of health disparities to the challenge of promoting smoking cessation among low SES smokers. These include: 1) Patient navigation; patient navigators are often lay persons, working as paid employees, who guide patients through the health care system and 2) Financial incentives; We propose to provide monetary incentives: $250 for smoking cessation within 6 months after study enrollment, and $500 for an additional 6 months of abstinence after the initial cessation. We will recruit/ randomize 352 smokers to a randomized controlled trial comparing the combination of Patient Navigation (delivered over 6 months) and Financial I ncentives versus Enhanced Traditional Care control condition (smoking cessation brochure/ list of cessation resources). The RCT will take place among adult daily smokers seen in the past year at BMC primary care practices, with a primary outcome of smoking cessation at one year. Follow-up by telephone, for both groups, will occur 6, 12, and 18 months after enrollment.
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Cigarette smoking is a highly significant health threat, responsible for > 480,000 deaths in the US each year, many due to cancer, and is the largest cause of preventable morbidity and mortality in the US. Primary care settings provide an opportunity to reach large proportions of low-income smokers, as 61% of such smokers are engaged in medical care. The proposed project addresses this under-utilization of available smoking cessation services which is occurring despite considerable interest among low-income patients about quitting/ receiving help with quitting. This intervention has the potential to increase the reach of existing services and in turn, to improve the public's health.
Patient financial incentives, while not yet used as standard of care for health promotion, are in the research stage for various types of conditions. Financial incentives are effective in promoting smoking cessation; but have not been extensively studied among low SES smokers. Financial incentives are a behavioral economic intervention that is effective in promoting smoking cessation, increasing cessation rates 3-fold compared to no incentives. We believe financial incentives merit further study, particularly in low SES populations. I ncentives for completing smoking cessation programs/ achieving abstinence may be particularly effective among low SES smokers because they: 1) can alleviate some of the financial strain that prevents low SES smokers from quitting (studies have shown that the stress from financial problems prevents patients from quitting, even though quitting smoking could save people large amounts of money); 2) promote short-term abstinence among smokers with mental illness and substance use, many of whom are low SES smokers; 3) provide a substitute reinforcer for smoking (e.g., in lieu of hobbies, physical activity, work satisfaction) often absent in environments of low SES smokers and 4) provide extrinsic motivation for patients to quit smoking, and may be particularly effective among low SES smokers, many of whom in our recent pilot study were found to have low levels of intrinsic motivation. Our strategy is to combine financial incentives with patient navigation, as the latter may "supercharge" the former, for the two interventions may work in complementary ways. We posit that incentives will augment people's willingness to connect with a navigator, and the navigator will put people in touch with resources/ environments in which the incentives can work.
Patient navigation holds promise as an intervention to reduce cancer disparities, but alone may be insufficient to promote smoking cessation. Patient navigators are often lay persons from the community who guide patients through the health care system so that they receive appropriate services. While patient navigation has been shown to be an effective intervention to reduce health care disparities, prior patient navigation studies have been limited to the realms of cancer screening and diagnosis. Preliminary findings from our pilot RCT of patient navigation to promote smoking cessation among low SES and minority primary care patients at Boston Medical Center suggest that a more potent intervention may be needed. While a patient navigator was able to link 37% of patients to treatment, she was unable to contact or meaningfully connect with 53% of patients. Thus, financial incentives may be used to increase participant motivation to connect with patient navigators.
Combining financial incentives with patient navigation may be an effective approach to promote cessation among low SES and minority smokers. Multicomponent interventions have shown the most promise in changing health behaviors in general, and in reducing health disparities. Barriers to behavior change among socially disadvantaged persons may be so large that no single intervention can be effective. We have therefore chosen to implement two intervention components, financial incentives and patient navigation, which have shown some promise in smoking cessation, and are currently being applied in the health disparities field to other health conditions. Our objectives and hypotheses are: Specific Aim I: To determine whether patient navigation and financial incentives increase the rates at which primary care patients engage in smoking cessation treatment. H1: Compared to control patients, those assigned to the intervention will be more likely to engage in smoking cessation treatment at six months post-enrollment.
Specific Aim II: To determine whether patient navigation and financial incentives increase the rates at which primary care patients quit smoking (our primary outcome), defined as biochemically confirmed cessation at twelve months using salivary cotinine levels. H1: Compared to ETC patients, those assigned to the patient navigation/ financial incentives intervention will be more likely to be abstinent at 12 months post-enrollment.
Subjects
Inclusion Criteria
Specify your inclusion criteria for each cohort. The following data was migrated from INSPIR I (if any). Eventually, the box below will go away. So please remove your answer from the box below and place it in the above text editor (green button) by cutting and pasting it. The box below should be left blank.
Exclusion Criteria
Specify your exclusion criteria for each cohort.
Order Number Criteria 1 planning to move out of the area within the next six months 2 cognitive impairments that preclude participation in study activities 3 severe illness or distress 5 actively using evidence-based smoking cessation treatment 6 transient residence or lack of a telephone for follow-up assessments.
The following data was migrated from INSPIR I (if any). Eventually, the box below will go away. So please remove your answer (if any) from the box below and place it in the above text editor (green button) by cutting and pasting it. The box below should be left blank. Only smoking cessation medications that are safe in pregnancy will be offered to/discussed with any subjects who are known to be pregnant. Women of child bearing potential will be informed if any smoking cessation medications are potentially unsafe in pregnancy. In general, it the patient's PCP who will be prescribing smoking cessation medications. 13.3 Discuss the research design including but not limited to such issues as: probability of group assignment, potential for subject to be randomized to placebo group, who is responsible for the randomization at local site, use of control subjects, etc.
We will conduct a randomized controlled trial (RCT), randomizing 552 patients to the intervention condition (patient navigation and financial incentives) or an enhanced traditional care (ETC) control condition. Our primary outcome is biochemically confirmed smoking cessation at 12 months. Our intervention is based on motivational interviewing principles (e.g., tailored to participant's level of confidence and importance of quitting) and behavioral economics to encourage patients to utilize smoking cessation resources (e.g., quit lines, discussing smoking cessation with their PCPs, smoking cessation groups).
Randomization to the study conditions will be by individual patient. We will randomize patients to condition using the Urn Randomization Program, which allows for randomization of participants to two randomization groups while balancing on additional variables. To ensure equivalence across treatment conditions, we will stratify random assignment on the basis of stage of change since this would likely impact study outcomes (e.g. the percent of persons who increased motivation to quit, engaged in treatment resources, and were abstinent). There is a risk of contamination between patients assigned to the navigation +incentives arm and those assigned to the ETC arm. We will minimize this risk by having the navigator based centrally in the Section of General I nternal Medicine; she would only have a presence in the clinics when meeting a newly enrolled participant. S/ he will be trained to work only with the patients assigned to the navigation + incentives arm.
Procedure
Describe in detail the experimental design, including all materials and all procedures to be performed in sequential order as they will be performed. Clarify which procedures/test articles are investigational and which are part of standard clinical care. This description may include:
1. methods 2. specific information concerning experimental interventions, such as dose and frequency of drug (and placebo) administration, or deception/debriefing process for social behavioral studies 3. number, frequency and duration of subject contacts (visits, telephone calls, mail outs, emails) 4. entire duration of participation for a single subject 5. any additional requirements of the subject (post treatment follow-up, diary cards, questionnaires, etc.
(Note: For multiple sites, indicate which of the procedures will be done at any other sites other than BUMC (see Study Site Information). Attach, in the Study Attachments section, copies of any surveys, questionnaires, and other data collection instruments.)
Enhanced traditional care (ETC) control condition. Patients randomized to the ETC control condition receive a low literacy smoking cessation brochure and a list of hospital and community resources for smoking cessation. The study research assistant will give these materials to all participants at the time of study enrollment regardless of study condition, as this intervention content is common to both treatment conditions. This control condition standardizes the provision of information regarding evidence-based smoking cessation resources, allowing for a more rigorous evaluation of the Patient Navigation/ Financial I ncentives intervention. I n routine clinical care at Boston Medical Center, medical assistants ask all patients in the primary care practices about their smoking status, which is documented in the medical record. I n usual care at BMC, patients do not receive a low literacy smoking cessation brochure or a list of hospital and community resources for smoking cessation. The brochure and list of resources are an enhancement of usual care and are provided to ETC control subjects upon enrollment.
All participants (those in ETC control condition, and patient navigation and financial incentives condition, described below) will complete assessments at baseline, 6, 12 and 18 months (please see attachment). Measurements assess the primary and secondary outcomes of the study, and potential mediating and moderating variables as well as process variables. A blinded, trained research assistant will administer survey assessments at the primary care practices (baseline) and over the telephone (6, 12, and 18-month) . All assessments require < 30 minutes to complete. Participants will receive incentives for completion of 6-, 12-and 18-month assessments.
For participants in the patient navigation and financial incentives condition, we will assess participants' perceived impact/ helpfulness of each intervention component at the 6-month assessment.
Participants in both study groups who self-report >7 days of abstinence at the 6, 12, or 18 month follow-up period will be asked to meet with a research assistant at the clinic or the participant's home to provide a saliva sample via oral swab for cotinine analysis (or a urine test if they are on nicotine replacement therapy). The saliva swab is a painless procedure that takes a few seconds.
Patient navigation and financial incentives condition
Patient navigation. Patients randomized to the intervention condition will receive a low literacy smoking cessation educational brochure and a list of hospital and community resources for smoking cessation (again, this intervention content is common to both treatment conditions). At the time of enrollment, intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General I nternal Medicine. Our two navigators will have completed high school, and will have had extensive experience doing community health outreach. Patients will receive up to four hours of patient navigation, largely in person, over a six-month period. We have not designated a specific number of calls/ meetings, but allot a maximum of four hours of patient navigation time per patient. If a subject calls several times and goes over the 4 hours, the patient navigator will refer the patients back to their primary care team for further assistance. The navigators will work flexible hours, making calls/ meeting patients on evenings and weekends as necessary. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services. The PHS Clinical Practice Guideline recommends the 5 As (i.e., Ask, Advise, Assess, Assist, and Arrange) as the primary model to promote smoking cessation. Several medical specialty organizations have integrated components of the 5 As into an abbreviated intervention: Ask, Advise, Refer. I n this model, health professionals ask patients about tobacco use, advise them to quit, and refer them to quit lines or web-based and local cessation programs. I n our intervention, we propose that Advise and Refer also become the responsibility of the patient navigator. For those patients who have already been advised by their PCPs to quit, the navigator can reinforce that message. "Refer" will be accomplished through referrals to one of the following: a quitline, the patient's PCP, or a health care-based smoking cessation group that offers counseling and pharmacotherapy. The navigator component complements and reinforces use of these services. In addition, some counseling is inherent to the patient navigator role. I f an individual is engaged in a cessation program and talking to a navigator, issues are bound to arise in discussion where the participant has questions, etc. While navigators will not provide a structured smoking cessation program per se, they will provide education and support to existing cessation programs.
Description of the patient navigation interactions. The first patient navigation meeting will often take place before or after a patient's medical appointment. Depending on the participants' availability, this meeting could take place on the day of enrollment or on a subsequent date. The meeting will be guided by a script that has already been developed (see attachment). The script uses motivational interviewing (MI ) strategies to do the following: (1) assess stage of change for smoking cessation; (2) assess and reinforce any prior abstinence from smoking and/ or any efforts made to reduce or quit smoking; (3) explore the patient's motivation to quit smoking, drawing on recent illness, financial situation, and family situation as appropriate; (4) advise about the risks of smoking/ benefits of quitting; (5) discuss past experience with utilizing cessation support; (6) describe/ discuss options for smoking cessation --quitline, PCP visit, smoking cessation groups --discussing the process and success achieved with each program, exploring the pros and cons of each option tailored to the patient's needs; (7) determine how the navigator can facilitate access to the preferred approach; (8) explore barriers to accepting a cessation referral (e.g. lack of trust, cost, misconceptions about treatment (e.g. that NRT is more harmful than cigarettes); (9) brainstorm strategies to address barriers; (10) elicit commitment to accept referral to smoking cessation treatment, if patient is willing, and (11) elicit commitment to accept another navigation call/ meeting and discuss timing. The navigator can also connect participants to resources to assist with problems that keep them from stopping smoking, such as insurance, housing, or financial problems. The patient navigator may also be in touch with the participant's primary care provider, asking him/ her to place a referral to a smoking cessation group, for example. The navigator will also document in the medical record any referrals that she has made to smoking cessation resources outside of Boston Medical Center.
Subsequent navigator-patient interactions follow a similar format, and will take place either in person or over the phone, according to the participant's preference. The length of the first meeting will vary depending on the individual participant, but should take no more than one hour.
Navigator training and evaluation. The Education Coordinator at the Brief Negotiated I nterview-Active Referral to Treatment (BNI -ART) I nstitute at BU School of Public Health, an experienced MI trainer with expertise in training patient navigators, will deliver a standard, validated MI training program to the navigators. This training will take place over 5 days and will focus on developing MI skills and delivery of the navigator intervention. MI skills will be learned through didactics, demonstrations, role-plays, reading assignments, and video. The navigators will be evaluated on both process (helpfulness, warmth, empathy), and content (intervention adherence). The navigators will practice the intervention protocol with two to three "practice" participants and achieve proficiency prior to delivering the intervention. Training will also include information about tobacco dependence and treatment, barriers to treatment engagement among low SES and minority patients, and treatment resources. Following training, Drs. Lasser and Quintiliani will meet weekly with the navigators to discuss difficult cases, and monthly to ensure skill maintenance by reviewing audiotapes of interactions and providing corrective feedback. Every other month, the Education Coordinator at BNI-ART will also review a randomly selected audiotape to provide an 'external' perspective on the navigator's performance and provide that feedback to Drs. Lasser and Quintiliani and both navigators. The Education Coordinator will not be engaged in the research, and thus is not listed on the protocol.
Preserving internal validity/treatment fidelity, and program tracking. The intervention is manual-based. After each patient interaction, the navigators complete a checklist of intervention components that were delivered. We will use these checklists to ensure that the intervention is delivered as intended, and to estimate intervention "dose" and treatment exposure. We will audiotape one interaction per participant with permission from the participant; Drs. Lasser and Quintiliani will monitor tapes for protocol adherence, auditing at least 50% of the tapes at the beginning of the intervention period, until adherence to the checklist reaches a proficiency threshold, and between 20-50% toward the end of the intervention period, to ensure continued adherence.
Financial incentives. The navigators will be aware that participants are eligible to receive financial incentives, but will not provide them to patients. The research assistant will provide incentives following assessments and biochemically confirmed cessation (described above; and a certificate of completion if a participant has attended a smoking cessation group). The financial incentives will be similar to those used by Volpp et al in an earlier successful smoking cessation study: $250 for cessation of smoking within six months after study enrollment, as confirmed by a salivary cotinine or urine anabasine/ anabatine test, and $500 for abstinence for an additional six months after the initial cessation, as confirmed by a salivary cotinine or urine anabasine/ anabatine test. Study staff will mail money in check form to patients who have successfully quit smoking or completed a smoking cessation group. Other studies (e.g. those that are NI H funded) of financial incentives to promote healthy behaviors among low SES participants are currently using checks to compensate patients.
4. entire duration of participation for a single subject 1. 18 months.
5. Any additional requirements of the subject (post treatment follow-up, diary cards, questionnaires, etc.
As noted, above, all participants will complete assessments at baseline (in person) , and at 6, 12 and 18 months (over the telephone; please attachments for each assessment). Measurements assess the primary and secondary outcomes of the study, and potential mediating and moderating variables as well as process variables. A blinded, trained research assistant will administer survey assessments at the primary care practices (baseline) and over the telephone (6, 12, and 18-month). All assessments require < 30 minutes to complete. Participants will receive incentives for completion of 6-, 12-and 18-month assessments. We will assess participants' perceived impact/ helpfulness of each intervention component through surveys (including open-ended questions) following the intervention.
Outcomes (Indicate anticipated primary and any secondary outcomes and how they will be measured):
Our primary outcome is smoking abstinence at 12 months post-enrollment. Because smokers who successfully quit for even a short period are more likely to quit long-term, we will measure the point prevalence of self-reported smoking cessation that is confirmed biochemically at 12 months. We define this outcome as no smoking within the past 7 days as defined by selfreported abstinence in the past 7 days AND biochemical validation of abstinence. Those who self-report >7 days of abstinence at the 6, 12, or 18 month follow-up period will be asked to meet with a research assistant at the clinic or the participant's home to provide a saliva sample via oral swab for cotinine analysis, which is the measure of choice because of its sensitivity and specificity. Salimetrics, LLC, State College, PA will conduct salivary cotinine analysis. I f a participant is using nicotine replacement therapy, the test of choice is a urine test for anabasine/ anabitine. Participants will receive $15 dollars to provide a saliva or urine sample. We categorize as smokers all patients who 1) self-report abstinence, but are identified as smokers via biochemical validation (cotinine level greater than 15, or positive anabasine/ anabitine ), 2) self-report abstinence, but refuse biochemical verification, or 3) cannot be located.
We will also study whether linkage to/ utilization of smoking cessation treatment at 6 and 12 months post-enrollment mediates the hypothesized primary outcome (smoking cessation). We have designated this outcome as a dichotomous variable, Y/ N, based on a) completion of > 1 quit line counseling session (based on report from MA DPH Quitworks program, or self-report if another quitline is used); OR b) > 1 PCP visit in which smoking cessation treatment is discussed (medical record review of progress notes); OR c) completion of > 1 session of a BMC smoking cessation group (medical record review or self-report if another group is used). We will also examine use of cigars or chewing tobacco as a secondary measure.
Estimated Duration of Enrollment (Indicate how long will it take to recruit the required sample size):
We estimate that it will take 8 months to recruit 552 patients, based on our recruitment experience from the pilot study.
Estimated Duration of Entire Study (Indicate estimated duration from initial IRB approval through data analysis to close of study):
We estimate the study will take 5 years; 2.5 years to complete the intervention and assessments, and an additional 2.5 years to conduct data analyses and write manuscripts.
Study Attachments
You must attach to this application all surveys, interviews, questionnaires, focus group outlines, etc. that will be used in this study. The IRB must review these materials as part of its review. If these items are included as part of the grant application they do not have to be submitted again. Failure to provide this information could result in a delay in IRB review. If some of the materials are not finalized-submit the DRAFT versions. The final versions will need to be approved by the IRB via an amendment PRIOR to use. Indicate why you chose the sample size proposed. Provide your sample size calculations. If this is a pilot study, this justification does not necessarily require a formal sample size calculation, but should provide a rationale for choosing the sample size proposed (e.g. to estimate a mean to a certain accuracy, to determine if the response rate is above a certain percentage, etc.) Note: Once the IRB approves a certain study sample size then you may not enroll beyond that sample size without first obtaining approval from the IRB. **** In determining your sample size be sure to allow for screen failures and study drop-outs. Explain how many evaluable subjects you will need to end up with to answer your study question and how many subjects you will need to enroll and consent to achieve this number. The IRB counts study subjects starting when they are screened/consented.
We have based our power calculations on estimates of the outcomes from prior research. While we will recruit more than 176 participants per study arm to account for a possible exclusion of non-smokers are the consent has been completed, we have powered the study to account for a 50% potential loss to follow-up of 176 participants per study arm, based on estimates from other studies. With an estimated sample size of 88 per study arm, we will have 88% power to detect a 5% vs. 20% difference in cessation rates between the 2 groups, with a one-sided alpha of .05.
Data Analysis
Provide a description of your plan for data analysis. State the types of comparisons you plan (e.g. comparison of means, comparison of proportions, regressions, analysis of variance). Which is the PRIMARY comparison/analysis? How will the analyses proposed relate to the primary purposes of your study? If you are doing qualitative research please state how comparisons will be made.
We will first run analyses to assess baseline comparability of the intervention and ETC control group. I n this analysis we will examine number of prior quit attempts in each group. I f necessary, we will control for any baseline differences in subsequent analyses.
We will then examine descriptive statistics of the primary outcome, smoking cessation at 12 months. For categorical outcomes of engagement and cessation, we report percentages and 95% confidence intervals, for continuous outcomes we examine means, standard deviations, and ranges. I n order to determine if the patient navigator/ financial incentives condition achieves greater smoking cessation at 12 month follow-up compared to ETC participants, we will compare groups using chi-square tests and note differences that are statistically significant at the =0.05 level. Analyses will be based on intent-to-treat. Because participants may receive varying "doses" of the patient navigation intervention, we will also analyze the intervention effect according to the total amount of time the navigator spends with each participant, and whether participants received a "minimum dose" of the intervention, defined as at least one in-person meeting with the navigator. We will use multiple logistic regression to control for potential confounders identified in bivariate analyses as well as variables of a priori clinical significance (gender, age, race, ethnicity, and insurance). We will utilize odds ratios with 95% confidence intervals to determine the relative magnitude of the adjusted association for each variable. I ndependent variables with strong correlations may result in collinearity. To address collinearity, we will construct separate models, each with one of the variables, and assess both the C statistic and the coefficients for the other variables in the model. We expect the majority of missing data to be due to dropouts due to moving or failure to remain in the study. We will investigate whether missing data is associated with patient characteristics. While data may not be missing completely at random, it may be reasonable to assume that data are missing at random. I f this is the case, multiple model based imputation methods originally developed for sample survey data is applicable to clinical trials with dropouts.
15.0 Potential Risk/Discomforts 15.1 Lists the possibilities for risks of harm or discomfort to subjects as a result of their participation in the research.
This study entails a risk of breach of confidentiality and privacy for completion of study surveys, self-reported smoking behaviors during follow-up, and/ or biochemical test results. Due to the financial interventions in this study, we will be collecting social security numbers (only from the study arm which receives financial incentives for smoking cessation) so that we can complete W-9 forms for participants receiving incentives. Accidental disclosure of social security numbers could lead to identity theft.
We will be asking participants about stress, chaos, and hassles in their life. There is a very small risk that answering some of these questions may cause participants some distress. Donation of salivary or urine samples for cotinine (or anabasine/ anabitine) testing poses minimal risk. I t is a simple sample of a few milliliters of saliva that can be obtained in seconds, or a standard urine test. Risk involved is limited to that of inconvenience and disclosure and breach of confidentiality.
15.2 Provide a description of how risks will be minimized.
We will use commercial-grade encryption to protect social security information in transit. Social security numbers will only be used to generate W-9 forms and will be deleted once they are no longer needed. Names and addresses will be stored in encrypted databases. These data will be viewable only by the research assistant. All other researchers will be able to view only participant I D numbers.
I n our pilot study we asked subjects about stress, chaos, and hassles. We did not observe that participants experienced distress. We believe the risk is minimal. Moreover, these questions are routinely asked in clinical care.
Urine and saliva samples will be coded with an identification number before being sent off-site for testing.
Patient navigators will be collecting data that may be personal and/ or sensitive-they will receive training in how to handle these data securely (e.g. subject logs in excel spreadsheets will be de-identified and kept on a password-protected computer) A list of numeric identifiers and subject names will be kept in a locked file cabinet in the navigator's office.
The PI with the assistance of the trained research assistant will perform all electronic medical record reviews, 6 and 12 months after the subject has signed the informed consent and enrolled in the study. She will review records for the following information: 1) whether the subject has had a PCP visit in which smoking cessation treatment is discussed 2) Whether subject attended > 1 session of a BMC smoking cessation group 3) Whether subject was prescribed a medication for smoking cessation during the study period (nicotine, bupropion, or Chantix) She will abstract data into a standard electronic form with a numeric identifier for each subject. The list of numeric identifiers and subject names will be kept on a password protected BMC computer in the PI 's office. AEs, SAEs, are defined in an attached detailed protocol. This is not a drug/device study or an intervention study. Only AEs/SAEs and UPs that are related or possibly related to the research will be collected and reported. This is a survey/interview/observational study. The only risks are related to confidentiality. No AEs/SAEs will be reported unless they meet the definition of an UP. Security /confidentiality breaches will be reported to the IRB as UPs.
A DSMP has been created using the BUMC DSMP template and attached in the Study Attachments section below.
Other definitions will be used for AEs/SAEs, and UPs. Describe below. We will NOT follow the BUMC policy for reporting AEs/SAEs and UPs. Describe alternate plan below.
*Unless specified the expectation is that BUMC policy will be followed for reporting AEs, SAEs, and UPs. Click here for link to BUMC policy This is a randomized controlled trial that is of minimal risk. The only risks are related to confidentiality. No AEs/ SAEs will be reported unless they meet the definition of an UP. Security / confidentiality breaches will be reported to the I RB as UPs.
Because this is a minimal risk randomized controlled trial, we will not convene a data safety and monitoring board. The sample size is too small to warrant any interim analyses. The principal risk subjects face is loss of confidentiality.
16.3 Frequency of monitoring. How often will the data be monitored by the entity/entities selected in question above? Provide additional details in the text box below.
DSMB/DMC/Independent Monitor will provide written reports annually DSMB/DMC/Independent Monitor will provide written reports every 6 months Other details about monitoring activities including by CRO & sponsor (describe below) 16.4 Stopping rules: for individual subjects and for the study as a whole. Not all studies require stopping rules. Describe any stopping rules in the box below.
Because the study is minimal risk, we will not implement stopping rules.
Study Attachments
Here Potential participants will be informed that they may or may not derive direct benefit from participation in the research. Participants' chances of achieving smoking cessation due to participation in this research study may be improved because all arms, including the Enhanced Traditional Care arm, entail the provision of features that may promote cessation that would not otherwise be available to participants per usual care at BMC. Participants may benefit from this study by being counseled by a patient navigator, who can help them become involved in smoking cessation programs. I f participants achieve cessation, they would benefit by reducing their risks for many tobacco-related diseases.
18.0 Potential Benefits -Cont.
18.1 Describe potential benefit(s) to society and scientific/medical knowledge in the research.
This research is being conducted with the primary goal of producing knowledge, and so the primary benefits to be gained are those related to the knowledge that the research may produce. An accurate understanding of the effects of this intervention on improving access to smoking cessation programs and leading to smoking cessation itself is crucial in reducing disparities.
Risk to Benefit Ratio
Describe how risks to subjects are reasonable in relation to anticipated benefits:
I n light of the tremendous benefits to public health and individual smokers of developing more effective smoking cessation programs, as well as our efforts, outlined above, to mitigate all risks associated with this study, we believe that this study presents a highly favorable risk-benefit ratio for participation.
Recruitment Procedures/Materials
Recruitment Procedures
Who will recruit subjects for this study?
Research subject (e.g., recruitment of family member into genetic studies) Third Party
Third Party Info:
Describe in detail how the research population will be identified and your methods for contacting potential subjects. If this study is a chart review or medical record review, explain how you will identify potential records to be reviewed.
The recruitment procedure is as follows: Research assistant 1) distributes study fact sheet in waiting room of the BMC general internal medicine primary care clinics; 2) invites patients to participate in the screening process to determine eligibility; 3) administers a brief pre-screening survey to determine eligibility; the screening does not involve collection of any PHI . Only responses without identifiers will be recorded for assessment of eligibility. 4) obtains written informed consent for eligible and interested patients . 5) confirm smoking status in EMR or carbon monoxide meter. 6) and then administers baseline assessment measures. We estimate that we can recruit 552 patients, as a full-time research assistant will be able to recruit 12 patients per week over eight months.
We will also employ a second recruitment strategy; the BU RESPECT registry. We attach an e-mail that will be sent out BMC patients who are part of the RESPECT registry.
Recruitment Material
Add any recruitment material that will be used in the 
Screening Procedures
20
.1 Indicate in the text boxes below if any screening procedures will be done to determine subject eligibility. The information in this section should be consistent with the Design/Procedure Section (specifically how will you screen people to determine that they meet the inclusion/exclusion criteria.)
Describe all screening procedures that will be conducted for this study:
When study staff interacts with interested individuals, study staff will ask if they can ask questions to screen him or her for eligibility.
What data will be collected during the screening procedure(s):
Study staff will ask potential participants if they smoked >10 cigarettes/day in the past week, if they are currently trying to quit smoking, if they speak English, if they plan to move within the next 6 months, if they are 18 years of age or older, if they have a telephone, and if they have a general internal medicine PCP at BMC; What data will be retained during the screening procedure(s):
For those who are eligible, we will retain name, study id, contact information, and eligibility status (yes/no). For those who are not eligible, we will retain their study ID, eligibility status (no) and reason they were ineligible.
Will subjects be consented prior to screening?
Yes No
What will happen to subjects' data if subjects "screen out"?
(If you expect a certain number of subjects to "screen out" be sure to allot for these subjects in the Sample Size/Data Analysis section.) Subjects who screen out will only have their study ID and reason for being ineligible recorded. ***Note:
In most instances, if identifiable data will be recorded as part of the screening, informed consent is required.
The IRB will determine whether verbal consent is allowed or whether written consent is required for screening.
Study Attachments
Here you can attach any screening forms and screening related documents. If yes, describe in detail the informed consent process, i.e. who will obtain consent and where, how long will subjects have to consider participating, is consent required prior to eligibility screening. If children will be enrolled, describe the assent process.
The research assistant will ask the participant if he/she can be asked a few screening questions, informing the participant that no information will be recorded in an identifiable way. After being found eligible, the research assistant will review the consent document with the potential participant. Following the consent document, she will describe the study and answer any questions the participant may have. She will then ask all those who are willing to participate to sign the form. If a person would like to think about it, they will be asked to contact us within 1 week if they are still interested in participating. The consenting procedure will take place in a private exam room in the primary care clinic.
I f a participant calls in about the study, e.g. from the ReSPECT registry, we will set up a time for the participant to come in and meet with the research assistant to learn more about the study. Indicate in the text box below if you intend to obtain assent from minor subjects. As a rule the IRB requires verbal assent for minors 7-11 years of age and written assent from minors ages 12-17 Note: if verbal consent is approved by the IRB for the parents/adult subjects (see the Verbal Consent/Assent section above), then verbal assent may be allowed also for 12-17 year olds. ** Be sure to discuss any plans for obtaining consent/assent from pregnant minors.
Consent by Substituted Judgment
Indicate in the text box below if you intend to obtain consent from a legally authorized representative for cognitively impaired/decisionally impaired subjects. Be sure to include information about how you will ascertain whether or not subjects are capable of consenting themselves and how you will determine who may provide consent for them. ***Note : consent can only be obtained from someone other than the subject with specific IRB approval.
Non-English Language Consent Forms:
Will this study require one or more non-English language consent forms?
Yes No
If you answered yes above, for each Non-English language you listed in the Subjects section, add the language to the What costs / potential costs will subjects incur (include travel, parking, medication, etc.)? How will the cost of research visits / procedures be covered? Will the subject (or the subject's insurance) be responsible for any research related costs? If yes, state specifically which items the subject (or the subject's insurance) will be responsible for and the cost of each.
The subjects will not be responsible for any research-related costs.
Payment / Course Credit
Payments If subjects will be paid (money, gift certificates, coupons, etc.) to participate in this research project, please note the total dollar amount (or dollar value amount) and distribution plan (one payment, pro-rated payment, paid upon completion, etc.) of the payment. Describe any other reimbursement that will be provided to subjects, (i.e. travel, parking, public transportation, etc.). Explain specifically how and when these reimbursements for expenses will be paid. Specify your plan for reimbursement if a subject withdraws from the study.
Subjects in both study arms will receive an incentive of $15, $20, and $25 for completion of the 6, 12, and 18-month assessments, respectively. Participants will receive an additional $15 for completion of the cotinine assay test (or a urine test if they are using nicotine replacement therapy), at the six, twelve and eighteen month follow-up assessments.
At each assessment, there will be a "retention lottery" across both study arms. Each participant will choose a number from 1-100 upon recruitment, e.g., "17." A number from 1-100 will be randomly generated at every assessment period. If the randomly drawn number was "17" (a 1 in 100 chance), the person would win $100. If more than one participant chooses the same number, each will win $100. To minimize loss to follow-up rates at each assessment, all participants will be entered into the lottery regardless of whether they quit smoking. Participants who withdraw from the study will not be included in the lottery. For the intervention group, participants will receive $100 for completion of a smoking-cessation program, $250 for biochemically confirmed smoking cessation within 6 months after study enrollment, and $400 for biochemically confirmed abstinence for an additional 6 months after the initial cessation.
Course Credit -If student subjects will receive course credit for their participation in this study. Explain below. 
